Clinical standards for antimicrobial stewardship in TB care
Brehm, T. T.; Akkerman, O. W.; Sotgiu, G.; Tiberi, S.; Chang, K.-C.; Dheda, K.; Duarte, R.; Vambe, D.; Udwadia, Z. F.; Chesov, D.; Mendelson, M.; Iswari Saktiawati, A. M.; van Ingen, J.; Eyuboglu, F. O.; Tängdén, T.; Quang Vo, L. N.; Riccardi, N.; Moschos, C.; Friedland, J. S.; Lillebaek, T.; Chandy, S. J.; Caminero, J. A.; Thwaites, G.; Gandra, S.; Thursky, K.; George, I. A.; Konstantynovska, O.; Fatima, R.; Yim, J.-J.; Kwak, N.; Olaru, I. D.; Gillespie, S.H.; Kherabi, Y.; Perl, S. H.; Grønningen, E.; Rodrigues, C.; Bjerrum, S.; Bange, F.; Cox, V.; Cirillo, D. M.; Saluzzo, F.; Hara, G. L.; Wagner, D.; Ismail, N.; Sloan, D. J.; Eshun-Wilsonova, I.; Zeng, M.; Cantero, C.; Vasankari, T.; Mandalakas, A.; Kay, A.; Ness, T.; Torrico, M. M.; Günther, G.; Kuksa, L.; Guglielmetti, L.; García-Basteiro, A. L.; Marks, G. B.; Pulcini, C.; Lange, C.
https://urn.fi/URN:NBN:fi-fe202601215635
Tiivistelmä
While antimicrobial stewardship (AMS) is essential for combating antimicrobial resistance (AMR), TB-specific AMS strategies remain poorly defined.
An international panel of 62 experts participated in a Delphi process. Using a 5-point Likert scale (5 = strong agreement; 1 = strong disagreement), participants evaluated 10 draft clinical standards developed by a core coordination team. A standard was adopted if ≥90% of respondents rated it three or higher, according to a predefined consensus threshold.
All 10 standards reached the consensus threshold and were adopted: Standard 1, integration of TB into national AMR action plans; Standard 2, implementation of TB surveillance systems; Standard 3, education of health care providers, individuals affected by TB, and the public; Standard 4, integration of TB into AMS activities; Standard 5, establishment of expert consultation services; Standard 6, targeted testing and preventive treatment for individuals at risk for TB; Standard 7, access to timely and comprehensive drug susceptibility testing; Standard 8, prioritisation of efficacy, safety, and resistance prevention in TB treatment regimens; Standard 9, clinical and microbiological monitoring of treatment response; and Standard 10, assessment of adherence, drug exposure, and resistance in treatment failure.
These clinical standards aim to support clinicians, programme managers, and public health authorities in implementing effective, TB-specific AMS strategies.
Kokoelmat
- Rinnakkaistallenteet [29335]
